Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 511

1.

Dynamics of human monocytes and airway macrophages during healthy aging and after transplant.

Byrne AJ, Powell JE, O'Sullivan BJ, Ogger PP, Hoffland A, Cook J, Bonner KL, Hewitt RJ, Wolf S, Ghai P, Walker SA, Lukowski SW, Molyneaux PL, Saglani S, Chambers DC, Maher TM, Lloyd CM.

J Exp Med. 2020 Mar 2;217(3). pii: e20191236. doi: 10.1084/jem.20191236.

PMID:
31917836
2.

Defining genetic risk factors for scleroderma-associated interstitial lung disease : IRF5 and STAT4 gene variants are associated with scleroderma while STAT4 is protective against scleroderma-associated interstitial lung disease.

Stock CJW, De Lauretis A, Visca D, Daccord C, Kokosi M, Kouranos V, Margaritopoulos G, George PM, Molyneaux PL, Nihtyanova S, Chua F, Maher TM, Ong V, Abraham DJ, Denton CP, Wells AU, Wain LV, Renzoni EA.

Clin Rheumatol. 2020 Jan 8. doi: 10.1007/s10067-019-04922-6. [Epub ahead of print]

PMID:
31916109
3.

Primary arthrodesis versus open reduction internal fixation for complete Lisfranc fracture dislocations: a retrospective study comparing functional and radiological outcomes.

Kirzner N, Teoh W, Toemoe S, Maher T, Mannambeth R, Hughes A, Goldbloom D, Curry H, Bedi H.

ANZ J Surg. 2019 Dec 19. doi: 10.1111/ans.15627. [Epub ahead of print]

PMID:
31858695
4.

Clinical quantification of the integrin αvβ6 by [18F]FB-A20FMDV2 positron emission tomography in healthy and fibrotic human lung (PETAL Study).

Lukey PT, Coello C, Gunn R, Parker C, Wilson FJ, Saleem A, Garman N, Costa M, Kendrick S, Onega M, Kang'ombe AR, Listanco A, Davies J, Ramada-Magalhaes J, Moz S, Fahy WA, Maher TM, Jenkins G, Passchier J, Marshall RP.

Eur J Nucl Med Mol Imaging. 2019 Dec 9. doi: 10.1007/s00259-019-04586-z. [Epub ahead of print]

PMID:
31814068
5.

Identifying causation in hypersensitivity pneumonitis: a British perspective.

Barber CM, Burge PS, Feary JR, Parfrey H, Renzoni EA, Spencer LG, Walters GI, Wiggans RE; GB HP Survey Participants .

BMJ Open Respir Res. 2019 Dec 3;6(1):e000469. doi: 10.1136/bmjresp-2019-000469. eCollection 2019.

6.

Discrimination of DNA Methylation Signal from Background Variation for Clinical Diagnostics.

Sanchez R, Yang X, Maher T, Mackenzie SA.

Int J Mol Sci. 2019 Oct 27;20(21). pii: E5343. doi: 10.3390/ijms20215343.

7.

The Role of the Lung's Microbiome in the Pathogenesis and Progression of Idiopathic Pulmonary Fibrosis.

Spagnolo P, Molyneaux PL, Bernardinello N, Cocconcelli E, Biondini D, Fracasso F, Tiné M, Saetta M, Maher TM, Balestro E.

Int J Mol Sci. 2019 Nov 10;20(22). pii: E5618. doi: 10.3390/ijms20225618. Review.

8.

Genome-Wide Association Study of Susceptibility to Idiopathic Pulmonary Fibrosis.

Allen RJ, Guillen-Guio B, Oldham JM, Ma SF, Dressen A, Paynton ML, Kraven LM, Obeidat M, Li X, Ng M, Braybrooke R, Molina-Molina M, Hobbs BD, Putman RK, Sakornsakolpat P, Booth HL, Fahy WA, Hart SP, Hill MR, Hirani N, Hubbard RB, McAnulty RJ, Millar AB, Navaratnam V, Oballa E, Parfrey H, Saini G, Whyte MKB, Zhang Y, Kaminski N, Adegunsoye A, Strek ME, Neighbors M, Sheng XR, Gudmundsson G, Gudnason V, Hatabu H, Lederer DJ, Manichaikul A, Newell JD Jr, O'Connor GT, Ortega VE, Xu H, Fingerlin TE, Bossé Y, Hao K, Joubert P, Nickle DC, Sin DD, Timens W, Furniss D, Morris AP, Zondervan K, Hall IP, Sayers I, Tobin MD, Maher TM, Cho MH, Hunninghake GM, Schwartz DA, Yaspan BL, Molyneaux PL, Flores C, Noth I, Jenkins RG, Wain LV.

Am J Respir Crit Care Med. 2019 Nov 11. doi: 10.1164/rccm.201905-1017OC. [Epub ahead of print]

PMID:
31710517
9.

Cost-effectiveness of Ambulatory Oxygen in improving quality of life in fibrotic lung disease: Preliminary evidence from the AmbOx Trial.

Whitty JA, Rankin J, Visca D, Tsipouri V, Mori L, Spencer L, Adamali H, Maher TM, Hopkinson NS, Birring SS, Farquhar M, Wells AU, Sestini P, Renzoni EA.

Eur Respir J. 2019 Nov 7. pii: 1901157. doi: 10.1183/13993003.01157-2019. [Epub ahead of print] No abstract available.

PMID:
31699838
10.

Physiological predictors of exertional oxygen desaturation in patients with fibrotic interstitial lung disease.

Alfieri V, Crisafulli E, Visca D, Chong WH, Stock C, Mori L, de Lauretis A, Tsipouri V, Chua F, Kouranos V, Kokosi M, Hogben C, Molyneaux PL, George PM, Maher TM, Chetta AA, Sestini P, Wells AU, Renzoni EA.

Eur Respir J. 2019 Nov 14. pii: 1901681. doi: 10.1183/13993003.01681-2019. [Epub ahead of print] No abstract available.

PMID:
31699833
11.

Effect of medium-chain TAG and exercise on satiety, energy intake and energy balance.

Maher T, El-Chab A, Shafat A, Clegg ME.

Br J Nutr. 2019 Dec 14;122(11):1313-1320. doi: 10.1017/S0007114519002186. Epub 2019 Nov 6.

PMID:
31690357
12.

Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease. Reply.

Distler O, Gahlemann M, Maher TM.

N Engl J Med. 2019 Oct 17;381(16):1596-1597. doi: 10.1056/NEJMc1910735. No abstract available.

PMID:
31618556
13.

Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial.

Maher TM, Corte TJ, Fischer A, Kreuter M, Lederer DJ, Molina-Molina M, Axmann J, Kirchgaessler KU, Samara K, Gilberg F, Cottin V.

Lancet Respir Med. 2019 Sep 27. pii: S2213-2600(19)30341-8. doi: 10.1016/S2213-2600(19)30341-8. [Epub ahead of print]

PMID:
31578169
14.

Current and future perspectives on management of systemic sclerosis-associated interstitial lung disease.

Distler O, Volkmann ER, Hoffmann-Vold AM, Maher TM.

Expert Rev Clin Immunol. 2019 Oct;15(10):1009-1017. doi: 10.1080/1744666X.2020.1668269. Epub 2019 Sep 30.

15.

Nintedanib in Progressive Fibrosing Interstitial Lung Diseases.

Flaherty KR, Wells AU, Cottin V, Devaraj A, Walsh SLF, Inoue Y, Richeldi L, Kolb M, Tetzlaff K, Stowasser S, Coeck C, Clerisme-Beaty E, Rosenstock B, Quaresma M, Haeufel T, Goeldner RG, Schlenker-Herceg R, Brown KK; INBUILD Trial Investigators.

N Engl J Med. 2019 Oct 31;381(18):1718-1727. doi: 10.1056/NEJMoa1908681. Epub 2019 Sep 29.

PMID:
31566307
16.

Modelling Forced Vital Capacity in Idiopathic Pulmonary Fibrosis: Optimising Trial Design.

Santermans E, Ford P, Kreuter M, Verbruggen N, Meyvisch P, Wuyts WA, Brown KK, Lederer DJ, Byrne AJ, Molyneaux PL, Sivananthan A, Moor CC, Maher TM, Wijsenbeek M.

Adv Ther. 2019 Nov;36(11):3059-3070. doi: 10.1007/s12325-019-01093-3. Epub 2019 Sep 29.

17.

Human PI3Kγ deficiency and its microbiota-dependent mouse model reveal immunodeficiency and tissue immunopathology.

Takeda AJ, Maher TJ, Zhang Y, Lanahan SM, Bucklin ML, Compton SR, Tyler PM, Comrie WA, Matsuda M, Olivier KN, Pittaluga S, McElwee JJ, Long Priel DA, Kuhns DB, Williams RL, Mustillo PJ, Wymann MP, Koneti Rao V, Lucas CL.

Nat Commun. 2019 Sep 25;10(1):4364. doi: 10.1038/s41467-019-12311-5.

18.

Interleukin-11 is a therapeutic target in idiopathic pulmonary fibrosis.

Ng B, Dong J, D'Agostino G, Viswanathan S, Widjaja AA, Lim WW, Ko NSJ, Tan J, Chothani SP, Huang B, Xie C, Pua CJ, Chacko AM, Guimarães-Camboa N, Evans SM, Byrne AJ, Maher TM, Liang J, Jiang D, Noble PW, Schafer S, Cook SA.

Sci Transl Med. 2019 Sep 25;11(511). pii: eaaw1237. doi: 10.1126/scitranslmed.aaw1237.

PMID:
31554736
19.

Antifibrotic therapy for idiopathic pulmonary fibrosis: time to treat.

Maher TM, Strek ME.

Respir Res. 2019 Sep 6;20(1):205. doi: 10.1186/s12931-019-1161-4. Review.

20.

Overlap of Genetic Risk between Interstitial Lung Abnormalities and Idiopathic Pulmonary Fibrosis.

Hobbs BD, Putman RK, Araki T, Nishino M, Gudmundsson G, Gudnason V, Eiriksdottir G, Zilhao Nogueira NR, Dupuis J, Xu H, O'Connor GT, Manichaikul A, Nguyen J, Podolanczuk AJ, Madahar P, Rotter JI, Lederer DJ, Barr RG, Rich SS, Ampleford EJ, Ortega VE, Peters SP, O'Neal WK, Newell JD Jr, Bleecker ER, Meyers DA, Allen RJ, Oldham JM, Ma SF, Noth I, Jenkins RG, Maher TM, Hubbard RB, Wain LV, Fingerlin TE, Schwartz DA, Washko GR, Rosas IO, Silverman EK, Hatabu H, Cho MH, Hunninghake GM.

Am J Respir Crit Care Med. 2019 Dec 1;200(11):1402-1413. doi: 10.1164/rccm.201903-0511OC.

PMID:
31339356

Supplemental Content

Loading ...
Support Center